Researchers have found a way to sneak peptides past the immune system by fitting them with cages that cover binding sites on the proteins like a hat. These prevent the binding sites from revealing the peptides' true nature as something from the outside.
The FDA approved Sanofi's Fluzone Intradermal Quadrivalent in adults age 18 through 64.
Researchers at the University of Maryland and Bethesda, MD-based Weinberg Medical Physics have created a startup called Iron Focus Medical that attempts to build on their prior research to commercialize a novel drug delivery system.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.
Saying it is on track to exceed its goal of having 5 key products in clinical development through 2015, Alnylam recently announced that it intends to focus on three strategic therapeutic areas, or what it dubs "STArs," as it races to commercialize its first candidate delivered using the RNAi pathway and reassure sometimes antsy investors.
ProNAi Therapeutics, a licensee of RNAi specialist Marina Biotech, reported positive results from its so-called DNAi-based candidate PNT2258 for non-Hodgkin lymphoma.
Because nanoparticles are so different in scale from other drugs on the market, drugmakers will need a way to make them in bulk and at a low cost, though still highly specific in form and function. To that end, researchers have developed a technique for making 3-D structures at the nanoscale, offering repeatable production that is also relatively inexpensive.
Insys Therapeutics, a combination drug developer and delivery specialist, won an orphan designation from the FDA for a gastric cancer treatment that delivers paclitaxel trapped in liposomes to make the common cancer drug more soluble and less toxic.
Researchers at Harvard University have demonstrated that a nonsurgical injection of programmable biomaterial can assemble in vivo into a 3-D structure to attack cancer cells and help to prevent other infectious diseases such as HIV.
Developer and supplier of drug delivery systems Unilife announced last week the signing of a worldwide, 10-year commercial supply agreement with a global pharmaceutical company for the use of its Depot-ject with an ocular injection therapy.
Oramed Pharmaceuticals announced last week that the company received $5 million through a stock sale and agreement with Guangxi Wuzhou Pharmaceutical, which purchased 696,378 restricted shares of Oramed stock at $7.18 per share.
Researchers at the University of Illinois at Urbana-Champaign have developed a hydrolyzable polymer that can be used as a drug delivery material.
Over the past few years, France's DBV Technologies has been financing its food allergy patch, and a new study showing that the patch helps children tolerate more peanuts has boosted the market value to the tune of $1 billion, according to a report from Bloomberg.
Catalent has signed on with Concord, MA-based Valerion Therapeutics to help develop delivery technology for the company's line of orphan genetic treatments.
Recipharm has purchased a manufacturing facility from Flamel Technologies in Pessac, France, for $13.2 million. The move is part of an effort to incorporate drug delivery technologies into its contract development business.
Microdermis' antiseptic skin product Provodine--which incorporates a novel dermal delivery system--has been adopted by the U.S. Army and will be used in West Africa against ebolavirus.
The National Institutes of Health recently awarded $20 million to a collaboration of researchers led by the Oak Crest Institute of Science to develop a novel intravaginal ring designed to prevent the spread of sexually transmitted HIV in women by delivering powerful combinations of antiretroviral drugs.
Arrowhead Research reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013.
Combining diagnostics and drug delivery is an ideal progression to improve the effectiveness and speed of treatment and a way to make drugs "smarter." To make one of these two-in-one systems, Singapore-based researchers developed a new biomarker that lights up to locate tumors and releases cancer drugs at the same time.
Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.